Cytosorbents (CTSO) Expected to Announce Quarterly Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) is anticipated to issue its quarterly earnings data after the market closes on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $10.09 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $1.10 on Thursday. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The firm’s 50-day simple moving average is $1.03 and its two-hundred day simple moving average is $1.04. The firm has a market cap of $60.15 million, a price-to-earnings ratio of -3.06 and a beta of 0.61. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Wall Street Analyst Weigh In

Several equities analysts recently commented on CTSO shares. StockNews.com assumed coverage on Cytosorbents in a research note on Saturday, February 22nd. They issued a “hold” rating on the stock. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Tuesday. Finally, HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Cytosorbents presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.